Lymphoma Trial, Recruiting NCT04107285 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Lymphoma
Back to Lymphoma

Lymphoma Trial, Recruiting

NCT04107285
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must be scheduled to receive one of the following approved CAR T cell treatments for lymphoma: axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, or brexacabtagene autoleucel
  • Your heart, lungs, blood, liver, and kidneys must be working well enough to receive CAR T cell therapy, as checked by your doctor
  • You must be well enough to carry out daily activities (on a standard health scale, your level of functioning must fall within a certain range — confirm with trial site)
  • You must have no signs of cancer that has spread to your brain or spinal cord at the time you join the study
  • You must be able to speak and understand English well enough to complete the study questionnaires and give your consent — if English is not your first language, you must be able to say you speak it "very well"

Who may not be able to join:

  • People who have signs or symptoms of cancer that has spread to the brain or nervous system, either at the start of the study or during it
  • People who have been diagnosed with a major mental health condition such as severe depression, bipolar disorder, or schizophrenia (based on medical records or self-report)
  • People who have a history of a brain-related degenerative disease, or a serious head injury that caused loss of consciousness for more than 60 minutes
  • People who have a history of epilepsy (seizure disorder)
  • People who currently misuse substances (such as drugs or alcohol) or have done so in the past
  • People whose vision or hearing problems would prevent them from completing the study assessments
  • People who cannot safely have an MRI scan — for example, those with certain metal implants, a pacemaker, a defibrillator, certain stents, or severe claustrophobia (fear of enclosed spaces)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 September 2019
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

changes in neurocognitive functions; changes in functional connectivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov